• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by Sharps Technology Inc.

    1/9/24 9:06:07 AM ET
    $STSS
    Medical/Dental Instruments
    Health Care
    Get the next $STSS alert in real time by email
    SC 13G 1 p24-0054sc13g.htm SHARPS TECHNOLOGY INC.

     

    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
     
     
    SCHEDULE 13G
     
     
    Under the Securities Exchange Act of 1934
     
    (Amendment No.  )*
     

    Sharps Technology Inc.

    (Name of Issuer)
     

    Common Stock, $0.0001 par value

    (Title of Class of Securities)
     

    82003F101

    (CUSIP Number)
     

    December 31, 2023

    (Date of event which requires filing of this statement)
     
     
    Check the appropriate box to designate the rule pursuant to which this Schedule 13G is filed:
     
    x Rule 13d-1(b)
    ¨ Rule 13d-1(c)
    ¨ Rule 13d-1(d)
     
    (Page 1 of 10 Pages)

     

    ______________________________

    *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

    CUSIP No. 82003F10113GPage 2 of 10 Pages

     

    1

    NAMES OF REPORTING PERSONS

    Empery Asset Management, LP

    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ¨

    (b) ¨

    3 SEC USE ONLY
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    Delaware

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
    5

    SOLE VOTING POWER

    0

    6

    SHARED VOTING POWER

    1,236,482 shares of Common Stock

    1,652,447 shares of Common Stock issuable upon exercise of Pre-Funded Warrants (See Item 4)*

    5,315,986 shares of Common Stock issuable upon exercise of Warrants (See Item 4)*

    7

    SOLE DISPOSITIVE POWER

    0

    8

    SHARED DISPOSITIVE POWER

    1,236,482 shares of Common Stock

    1,652,447 shares of Common Stock issuable upon exercise of Pre-Funded Warrants (See Item 4)*

    5,315,986 shares of Common Stock issuable upon exercise of Warrants (See Item 4)*

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    1,236,482 shares of Common Stock

    1,652,447 shares of Common Stock issuable upon exercise of Pre-Funded Warrants (See Item 4)*

    5,315,986 shares of Common Stock issuable upon exercise of Warrants (See Item 4)*

    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ¨
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    9.99% (See Item 4)*

    12

    TYPE OF REPORTING PERSON

    PN

             

     

    * As more fully described in Item 4, the Warrants are subject to a 4.99% blocker (other than the pre-funded warrants, which have a 9.99% blocker), and the percentage set forth in row (11) gives effect to such blockers. However, as more fully described in Item 4, the securities reported in rows (6), (8) and (9) show the number of shares of Common Stock that would be issuable upon full exercise of such reported securities and do not give effect to such blockers. Therefore, the actual number of shares of Common Stock beneficially owned by such Reporting Person, after giving effect to such blockers, is less than the number of securities reported in rows (6), (8) and (9).

     

    CUSIP No. 82003F10113GPage 3 of 10 Pages

     

    1

    NAMES OF REPORTING PERSONS

    Ryan M. Lane

    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ¨

    (b) ¨

    3 SEC USE ONLY
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    United States

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
    5

    SOLE VOTING POWER

    0

    6

    SHARED VOTING POWER

    1,236,482 shares of Common Stock

    1,652,447 shares of Common Stock issuable upon exercise of Pre-Funded Warrants (See Item 4)*

    5,315,986 shares of Common Stock issuable upon exercise of Warrants (See Item 4)*

    7

    SOLE DISPOSITIVE POWER

    0

    8

    SHARED DISPOSITIVE POWER

    1,236,482 shares of Common Stock

    1,652,447 shares of Common Stock issuable upon exercise of Pre-Funded Warrants (See Item 4)*

    5,315,986 shares of Common Stock issuable upon exercise of Warrants (See Item 4)*

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    1,236,482 shares of Common Stock

    1,652,447 shares of Common Stock issuable upon exercise of Pre-Funded Warrants (See Item 4)*

    5,315,986 shares of Common Stock issuable upon exercise of Warrants (See Item 4)*

    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ¨
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    9.99% (See Item 4)*

    12

    TYPE OF REPORTING PERSON

    IN

             

     

    * As more fully described in Item 4, the Warrants are subject to a 4.99% blocker (other than the pre-funded warrants, which have a 9.99% blocker), and the percentage set forth in row (11) gives effect to such blockers. However, as more fully described in Item 4, the securities reported in rows (6), (8) and (9) show the number of shares of Common Stock that would be issuable upon full exercise of such reported securities and do not give effect to such blockers. Therefore, the actual number of shares of Common Stock beneficially owned by such Reporting Person, after giving effect to such blockers, is less than the number of securities reported in rows (6), (8) and (9).

     

    CUSIP No. 82003F10113GPage 4 of 10 Pages

     

    1

    NAMES OF REPORTING PERSONS

    Martin D. Hoe

    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ¨

    (b) ¨

    3 SEC USE ONLY
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    United States

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
    5

    SOLE VOTING POWER

    0

    6

    SHARED VOTING POWER

    1,236,482 shares of Common Stock

    1,652,447 shares of Common Stock issuable upon exercise of Pre-Funded Warrants (See Item 4)*

    5,315,986 shares of Common Stock issuable upon exercise of Warrants (See Item 4)*

    7

    SOLE DISPOSITIVE POWER

    0

    8

    SHARED DISPOSITIVE POWER

    1,236,482 shares of Common Stock

    1,652,447 shares of Common Stock issuable upon exercise of Pre-Funded Warrants (See Item 4)*

    5,315,986 shares of Common Stock issuable upon exercise of Warrants (See Item 4)*

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    1,236,482 shares of Common Stock

    1,652,447 shares of Common Stock issuable upon exercise of Pre-Funded Warrants (See Item 4)*

    5,315,986 shares of Common Stock issuable upon exercise of Warrants (See Item 4)*

    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ¨
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    9.99% (See Item 4)*

    12

    TYPE OF REPORTING PERSON

    IN

             

     

    * As more fully described in Item 4, the Warrants are subject to a 4.99% blocker (other than the pre-funded warrants, which have a 9.99% blocker), and the percentage set forth in row (11) gives effect to such blockers. However, as more fully described in Item 4, the securities reported in rows (6), (8) and (9) show the number of shares of Common Stock that would be issuable upon full exercise of such reported securities and do not give effect to such blockers. Therefore, the actual number of shares of Common Stock beneficially owned by such Reporting Person, after giving effect to such blockers, is less than the number of securities reported in rows (6), (8) and (9).

     

    CUSIP No. 82003F10113GPage 5 of 10 Pages

     

    Item 1(a). NAME OF ISSUER:
       
      The name of the issuer is Sharps Technology Inc. (the "Company").

     

    Item 1(b). ADDRESS OF ISSUER'S PRINCIPAL EXECUTIVE OFFICES:
       
      The Company's principal executive offices are located at 105 Maxess Road, Melville, NY 11747.

     

    Item 2(a). NAME OF PERSON FILING:
       
      This statement is filed by the entities and persons listed below, who are collectively referred to herein as "Reporting Persons," with respect to the Common Stock (as defined in Item 2(d) below) of the Company:
       
      Investment Manager
       
      (i) Empery Asset Management, LP (the "Investment Manager"), with respect to the shares of Common Stock held by, and underlying the Reported Warrants (as defined below) held by, funds to which the Investment Manager serves as investment manager (the "Empery Funds").
       
      Reporting Individuals
       
      (ii) Mr. Ryan M. Lane ("Mr. Lane"), with respect to the shares of Common Stock held by, and underlying the Reported Warrants held by, the Empery Funds.
       
      (iii) Mr. Martin D. Hoe ("Mr. Hoe"), with respect to the shares of Common Stock held by, and underlying the Reported Warrants held by, the Empery Funds.
       
      The Investment Manager serves as the investment manager to each of the Empery Funds. Each of Mr. Lane and Mr. Hoe (the "Reporting Individuals") is a Managing Member of Empery AM GP, LLC (the "General Partner"), the general partner of the Investment Manager.

     

    Item 2(b). ADDRESS OF PRINCIPAL BUSINESS OFFICE OR, IF NONE, RESIDENCE:
       
     

    The address of the business office of each of the Reporting Persons is:

     

    1 Rockefeller Plaza, Suite 1205

    New York, New York 10020

     

    CUSIP No. 82003F10113GPage 6 of 10 Pages

     

    Item 2(c). CITIZENSHIP:
       
      Citizenship is set forth in Row 4 of the cover page for each Reporting Person hereto and is incorporated herein by reference for each such Reporting Person.

     

    Item 2(d). TITLE OF CLASS OF SECURITIES:
       
      Common Stock, $0.0001 par value (the "Common Stock")

     

    Item 2(e). CUSIP NUMBER:
       
      82003F101

     

    Item 3. IF THIS STATEMENT IS FILED PURSUANT TO RULES 13d-1(b) OR 13d-2(b) OR (c), CHECK WHETHER THE PERSON FILING IS A:

     

      (a) ¨ Broker or dealer registered under Section 15 of the Act,
      (b) ¨ Bank as defined in Section 3(a)(6) of the Act,
      (c) ¨ Insurance Company as defined in Section 3(a)(19) of the Act,
      (d) ¨ Investment Company registered under Section 8 of the Investment Company Act of 1940,
      (e) x Investment Adviser registered under Section 203 of the Investment Advisers Act of 1940,
      (f) ¨ Employee Benefit Plan or Endowment Fund in accordance with Rule 13d-1(b)(1)(ii)(F),
      (g) ¨ Parent Holding Company or control person in accordance with Rule 13d-1(b)(1)(ii)(G),
      (h) ¨ Savings Association as defined in Section 3(b) of the Federal Deposit Insurance Act,
      (i) ¨ Church Plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act of 1940,
      (j) ¨ A non-U.S. institution in accordance with Rule 13d-1(b)(1)(ii)(J);
      (k) ¨ Group, in accordance with Rule 13d-1(b)(1)(ii)(K).

     

      If filing as a non-U.S. institution in accordance with Rule 13d-1(b)(1)(ii)(J), please
      specify the type of institution:  

     

    CUSIP No. 23257B10713GPage 7 of 10 Pages

     

    Item 4. OWNERSHIP.
       
      The information as of the date of the event which requires filing of this statement required by Items 4(a) – (c) is set forth in Rows 5 – 11 of the cover page for each Reporting Person hereto and is incorporated herein by reference for each such Reporting Person.  The percentage set forth in Row 11 of the cover page for each Reporting Person is based on 15,274,457 shares of Common Stock issued and outstanding as of November 14, 2023, as represented in the Company’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 14, 2023 and assumes the exercise of the Company’s reported warrants (the “Reported Warrants”) subject to the Blockers (as defined below).
       
      Pursuant to the terms of the Reported Warrants, the Reporting Persons cannot exercise the Reported Warrants to the extent the Reporting Persons would beneficially own, after any such exercise, more than 4.99% of the outstanding shares of Common Stock (other than the Pre-Funded Warrants, which cannot be exercised to the extent the Reporting Person would beneficially own, after such exercise, more than 9.99% of the outstanding shares of Common Stock) (the "Blockers"), and the percentage set forth in Row 11 of the cover page for each Reporting Person gives effect to the Blockers.  Consequently, as of the date of the event which requires the filing of this statement, the Reporting Persons were not able to exercise all of the Reported Warrants due to the Blockers.
       
      The Investment Manager, which serves as the investment manager to the Empery Funds, may be deemed to be the beneficial owner of all shares of Common Stock held by, and underlying the Reported Warrants (subject to the Blockers) held by, the Empery Funds.  Each of the Reporting Individuals, as Managing Members of the General Partner of the Investment Manager with the power to exercise investment discretion, may be deemed to be the beneficial owner of all shares of Common Stock held by, and underlying the Reported Warrants (subject to the Blockers) held by, the Empery Funds.  The foregoing should not be construed in and of itself as an admission by any Reporting Person as to beneficial ownership of shares of Common Stock owned by another Reporting Person.  Each of the Empery Funds and the Reporting Individuals hereby disclaims any beneficial ownership of any such shares of Common Stock.

     

    Item 5. OWNERSHIP OF FIVE PERCENT OR LESS OF A CLASS.
       
      Not applicable.

     

     

    CUSIP No. 82003F10113GPage 8 of 10 Pages

     

    Item 6. OWNERSHIP OF MORE THAN FIVE PERCENT ON BEHALF OF ANOTHER PERSON.
       
      See Item 2(a) above.

     

    Item 7. IDENTIFICATION AND CLASSIFICATION OF THE SUBSIDIARY WHICH ACQUIRED THE SECURITY BEING REPORTED ON BY THE PARENT HOLDING COMPANY.
       
      Not applicable.

     

    Item 8. IDENTIFICATION AND CLASSIFICATION OF MEMBERS OF THE GROUP.
       
      Not applicable.

     

    Item 9. NOTICE OF DISSOLUTION OF GROUP.
       
      Not applicable.

     

    Item 10. CERTIFICATION.
       
      Each of the Reporting Persons hereby makes the following certification:
       
      By signing below each Reporting Person certifies that, to the best of its knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

     

    CUSIP No. 82003F10113GPage 9 of 10 Pages

     

    SIGNATURES

    After reasonable inquiry and to the best of our knowledge and belief, the undersigned certify that the information set forth in this statement is true, complete and correct.

    DATED: January 9, 2024

     

       
      EMPERY ASSET MANAGEMENT, LP
      By: EMPERY AM GP, LLC, its General Partner
       
      By: /s/ Ryan M. Lane
      Name:  Ryan M. Lane
      Title:  Managing Member
       
      /s/ Ryan M. Lane
      Ryan M. Lane
       
      /s/ Martin D. Hoe
      Martin D. Hoe

     

     

    CUSIP No. 82003F10113GPage 10 of 10 Pages

    EXHIBIT 1

    JOINT ACQUISITION STATEMENT
    PURSUANT TO RULE 13d-1(k)

    The undersigned acknowledge and agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G shall be filed on behalf of each of the undersigned without the necessity of filing additional joint acquisition statements. The undersigned acknowledge that each shall be responsible for the timely filing of such amendments, and for the completeness and accuracy of the information concerning him or it contained therein, but shall not be responsible for the completeness and accuracy of the information concerning the others, except to the extent that he or it knows or has reason to believe that such information is inaccurate.

    DATED: January 9, 2024

     

       
      EMPERY ASSET MANAGEMENT, LP
      By: EMPERY AM GP, LLC, its General Partner
       
      By: /s/ Ryan M. Lane
      Name:  Ryan M. Lane
      Title:  Managing Member
       
      /s/ Ryan M. Lane
      Ryan M. Lane
       
      /s/ Martin D. Hoe
      Martin D. Hoe

     

     

    Get the next $STSS alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $STSS

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $STSS
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Sharps Technology Receives ~$100K Initial Purchase Order from Hungarian Vaccine Provider for SecureGard™ Syringes

      Sharps also received an initial qualification purchase order for DisGard™ single-use Sharps Recovery System Company transitions to revenue producing with second purchase order, bringing total recent orders to approximately $500,000 for the quarter NEW YORK, May 06, 2025 (GLOBE NEWSWIRE) -- Sharps Technology, Inc. (NASDAQ: "STSS" and "STSSW") ("Sharps"), an innovative medical device and pharmaceutical packaging company offering patented, best-in-class smart-safety syringe products to the healthcare industry, announces the receipt of a $100,000 purchase order from a Hungarian vaccine provider. This order supports the recently announced $400,000 SoloGard™ order, which is part o

      5/6/25 7:00:00 AM ET
      $STSS
      Medical/Dental Instruments
      Health Care
    • Sharps Technology Secures $400K Initial Purchase Order from U.S. Leader in IV Flushing Solutions as Part of $50 Million SoloGard Supply Agreement

      Milestone order marks first commercial revenue for Sharps Technology under multi-year, 500-million syringe agreementInvestments in best-in-class manufacturing equipment position Sharps to offer differentiated high-volume syringe production to meet long-term contract demand NEW YORK, April 30, 2025 (GLOBE NEWSWIRE) -- Sharps Technology, Inc. (NASDAQ: "STSS" and "STSSW") ("Sharps"), an innovative medical device and pharmaceutical packaging company offering patented, best-in-class smart-safety syringe products to the healthcare industry, today announced the receipt of a $400,000 purchase order from a U.S. leader in IV flushing solutions. This marks the first order under the previously announ

      4/30/25 7:00:00 AM ET
      $STSS
      Medical/Dental Instruments
      Health Care
    • Sharps Technology Announces Reverse Stock Split

      NEW YORK, April 24, 2025 (GLOBE NEWSWIRE) -- Sharps Technology, Inc. (NASDAQ: "STSS" and "STSSW") ("Sharps"), an innovative medical device and pharmaceutical packaging company offering patented, best-in-class smart-safety syringe products to the healthcare industry, today announced that it will effect a 1-for-300 reverse stock split (the "reverse split") of its common stock, par value $0.0001 per share (the "Common Stock"), that will become effective on April 27, 2025 at 11:59 PM Eastern Time, before the opening of trading on The Nasdaq Capital Market ("Nasdaq"). Sharps has requested that its Common Stock begin trading on April 28, 2025, on a post-reverse split basis on the Nasdaq under th

      4/24/25 11:00:00 AM ET
      $STSS
      Medical/Dental Instruments
      Health Care

    $STSS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Large owner Bank Of America Corp /De/

      4 - Sharps Technology Inc. (0001737995) (Issuer)

      5/6/25 4:27:50 PM ET
      $STSS
      Medical/Dental Instruments
      Health Care
    • Chief Executive Officer Hayes Robert Michael bought $10,750 worth of shares (300,000 units at $0.04), increasing direct ownership by 297% to 400,882 units (SEC Form 4)

      4 - Sharps Technology Inc. (0001737995) (Issuer)

      4/1/25 5:24:02 PM ET
      $STSS
      Medical/Dental Instruments
      Health Care
    • Amendment: Chief Executive Officer Hayes Robert Michael bought $10,072 worth of shares (5,000 units at $2.01), increasing direct ownership by 115% to 9,358 units (SEC Form 4)

      4/A - Sharps Technology Inc. (0001737995) (Issuer)

      12/6/24 5:15:10 PM ET
      $STSS
      Medical/Dental Instruments
      Health Care

    $STSS
    SEC Filings

    See more
    • SEC Form SCHEDULE 13G filed by Sharps Technology Inc.

      SCHEDULE 13G - Sharps Technology Inc. (0001737995) (Subject)

      5/7/25 3:55:46 PM ET
      $STSS
      Medical/Dental Instruments
      Health Care
    • Sharps Technology Inc. filed SEC Form 8-K: Other Events

      8-K - Sharps Technology Inc. (0001737995) (Filer)

      5/7/25 9:00:22 AM ET
      $STSS
      Medical/Dental Instruments
      Health Care
    • Sharps Technology Inc. filed SEC Form 8-K: Regulation FD Disclosure

      8-K - Sharps Technology Inc. (0001737995) (Filer)

      5/6/25 8:00:37 AM ET
      $STSS
      Medical/Dental Instruments
      Health Care

    $STSS
    Financials

    Live finance-specific insights

    See more
    • Soligenix and Sharps Technology Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

      ORLANDO, FL / ACCESSWIRE / June 7, 2024 / RedChip Companies will air interviews with Soligenix, Inc. (NASDAQ:SNGX) and Sharps Technology Inc. (NASDAQ:STSS) on the RedChip Small Stocks, Big Money™ show, a sponsored program on Bloomberg TV, this Saturday, June 8, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the U.S.Access the interviews in their entirety at:Soligenix: https://www.redchip.com/assets/access/sngx_accessSharps Technology: https://www.redchip.com/assets/access/stss_accessIn an exclusive interview, Christopher J. Schaber, PhD, President and Chief Executive Officer of Soligenix, appears on the RedChip Small Stocks Big Money™ show on B

      6/7/24 9:00:00 AM ET
      $SNGX
      $STSS
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Medical/Dental Instruments
    • Sharps Technology, Reviva Pharmaceuticals, and American Resources Corp. Interviews to Air on the RedChip Money Report(R) on Bloomberg TV

      ORLANDO, FL / ACCESSWIRE / September 29, 2023 / RedChip Companies will air interviews with Sharps Technology, Inc. (NASDAQ:STSS), Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) and American Resources Corp. (NASDAQ:AREC) on The RedChip Money Report®, a sponsored program on Bloomberg TV, this Saturday, September 30, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the U.S.Access the interviews in their entirety at:Sharps Technology: https://www.redchip.com/assets/access/stss_accessReviva Pharmaceuticals: https://www.redchip.com/assets/access/rvph_accessAmerican Resources Corp: https://www.redchip.com/assets/access/arec_accessAbout The RedChip

      9/29/23 9:00:00 AM ET
      $AREC
      $RVPH
      $STSS
      Coal Mining
      Energy
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • RedChip Launches 'Small Stocks, Big Money' Podcast

      New podcast series shines a spotlight on undervalued small-cap and microcap stocksORLANDO, FL / ACCESSWIRE / August 2, 2023 / RedChip Companies, a renowned international investor relations firm specializing in microcap and small-cap companies,announce the launch of its much-anticipated podcast series, "Small Stocks, Big Money."Hosted by RedChip CEO Dave Gentry and Associate Director Barrett Boone, the "Small Stocks, Big Money" podcast aims to offer a first-hand look at undiscovered small-cap and microcap stocks before they catch the attention of bigger Wall Street players. The series features in-depth interviews with executives from some of the top names in smaller cap stocks, providing list

      8/2/23 12:45:00 PM ET
      $BFRG
      $LTRN
      $RVPH
      $STSS
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Medical/Dental Instruments
      Pharmaceuticals and Biotechnology

    $STSS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Sharps Technology Inc.

      SC 13G/A - Sharps Technology Inc. (0001737995) (Subject)

      11/13/24 4:50:17 PM ET
      $STSS
      Medical/Dental Instruments
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Sharps Technology Inc.

      SC 13G/A - Sharps Technology Inc. (0001737995) (Subject)

      10/9/24 9:01:14 AM ET
      $STSS
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G filed by Sharps Technology Inc.

      SC 13G - Sharps Technology Inc. (0001737995) (Subject)

      2/14/24 11:14:11 AM ET
      $STSS
      Medical/Dental Instruments
      Health Care

    $STSS
    Leadership Updates

    Live Leadership Updates

    See more
    • Sharps Technology Planning To Collaborate With Roncadelle To Support Global Distribution And Sales Of High Quality, Innovative, Safer Drug Delivery Systems

      NEW YORK, Feb. 16, 2024 (GLOBE NEWSWIRE) -- Sharps Technology, Inc., (NASDAQ:STSS) (NASDAQ:STSSW), an innovative medical device and pharmaceutical packaging company offering patented, best-in-class syringe products, is working to create new sales and distribution opportunities through the addition of new North American 3PL partnerships to expand its reach into the global healthcare market. These additional third-party logistics partnerships, along with a developing alliance with Roncadelle Operations, a driving force in the development of safe, novel medical drug delivery devices, would combine the strengths and capabilities of the two companies to develop, market and distribute unique dru

      2/16/24 2:42:54 PM ET
      $STSS
      Medical/Dental Instruments
      Health Care
    • Sharps Technology Appoints Industry Sales and Manufacturing Leader Ben Scheu as Senior Director of Sales

      Key appointment with demonstrated experience in leading sales and marketing operations to oversee commercial initiatives as the Company launches its specialty smart safety syringe products to the market Product qualification and sales initiatives underway as company prepares for U.S. commercial operations NEW YORK, July 12, 2023 (GLOBE NEWSWIRE) -- Sharps Technology, Inc. (the "Company") (NASDAQ: "STSS" and "STSSW"), an innovative medical device and drug delivery Company offering patented, best-in-class syringe products, is pleased to announce the appointment of Ben Scheu as Senior Director of Sales to lead commercial operations as the Company prepares to launch products to the market.

      7/12/23 8:33:00 AM ET
      $STSS
      Medical/Dental Instruments
      Health Care
    • Sharps Technology Appoints Justin Page as Vice President of Technical Operations

      NEW YORK, Feb. 09, 2023 (GLOBE NEWSWIRE) -- Sharps Technology, Inc. (the "Company", "Sharps") (NASDAQ: "STSS" and "STSSW"), an innovative medical device and drug delivery Company offering patented, best-in-class syringe products, appoints Justin Page as Vice President of Technical Operations. In his role, Mr. Page will be responsible for managing all aspects of Sharps' engineering operations. His primary focus will be to provide the leadership and technical expertise to support the prefillable syringe collaboration with Nephron Pharmaceuticals at the InjectEZ facility. These efforts will include the support for the injection molding of the specialty components and the high speed assembl

      2/9/23 9:21:23 AM ET
      $STSS
      Medical/Dental Instruments
      Health Care

    $STSS
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Executive Officer Hayes Robert Michael bought $10,750 worth of shares (300,000 units at $0.04), increasing direct ownership by 297% to 400,882 units (SEC Form 4)

      4 - Sharps Technology Inc. (0001737995) (Issuer)

      4/1/25 5:24:02 PM ET
      $STSS
      Medical/Dental Instruments
      Health Care
    • Amendment: Chief Executive Officer Hayes Robert Michael bought $10,072 worth of shares (5,000 units at $2.01), increasing direct ownership by 115% to 9,358 units (SEC Form 4)

      4/A - Sharps Technology Inc. (0001737995) (Issuer)

      12/6/24 5:15:10 PM ET
      $STSS
      Medical/Dental Instruments
      Health Care
    • Chief Executive Officer Hayes Robert Michael bought $10,072 worth of shares (5,000 units at $2.01), increasing direct ownership by 5% to 100,882 units (SEC Form 4)

      4 - Sharps Technology Inc. (0001737995) (Issuer)

      12/5/24 6:12:59 PM ET
      $STSS
      Medical/Dental Instruments
      Health Care